ONC 201

Drug Profile

ONC 201

Alternative Names: NSC-350625; ONC201; TIC 10; TRAIL-inducing compound 10

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oncoceutics
  • Developer Case Comprehensive Cancer Center; Fox Chase Cancer Center; Oncoceutics; Rutgers; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Imidazoles; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Endometrial cancer; Glioblastoma; Glioma; Neuroendocrine tumours
  • Phase I/II Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Preclinical Colorectal cancer; Mantle-cell lymphoma; Pancreatic cancer
  • No development reported Solid tumours

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule)
  • 21 Apr 2018 Pharmacodynamics data from a preclinical trial in Neuroendocrine tumours presented at the 109th Annual Meeting of the American Association for Cancer Research
  • 10 Apr 2018 Phase-II clinical trials in Breast cancer (Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO) (NCT03394027)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top